Scrip
>>Business

SillaJen IPO Priced Low But Hopes High As Pexa-Vec Progresses

01 Dec 2016

SillaJen, a South Korean venture that has been under investors' radars, is set to float at the lower end of its range as investors focus on the potential of its lead asset Pexa-Vec for liver cancer.

SillaJen Inc. has priced its shares at the bottom of the proposed band for a domestic initial public offering but has nevertheless drawn robust interest from retail investors who are counting on the potential of the South Korean venture’s oncolytic virus-based immunotherapy.

During the book building for the IPO, SillaJen's shares were priced at KRW15,000 ($12.84), the bottom of the proposed band...